‘We are not good at translating lab science into new medicines for patients’ – 20 January 2020

The discovery of “pioneer medicines” (i.e. those acting via novel molecular targets) has proven to be an immensely complex, long term, expensive and high risk endeavour. Despite formidable investments by the pharmaceutical industry and public/ charitable funders, over the past few decades in both infrastructure and technology, the success rates have remained low. During his presentation, Prof. Bountra discussed ways in which we can pool resources to share risk, reduce duplication, improve translation, minimise patient harm, and help industry discover new medicines for society.

Chas Bountra is Professor of Translational Medicine at the Nuffield Department of Medicine, University of Oxford. He is Co-Director of the Oxford Martin Programme on Affordable Medicines and has been made Oxford’s new Pro Vice-Chancellor, Innovation. 

Listen to the podcast of Prof. Bountra’s lecture here.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: